Pioglitazone may reduce body fat inflammation in insulin resistance

Public Library of Science

Published on 2014

Pioglitazone may reduce body fat inflammation in insulin resistance

Summary

This study re-examined fat tissue from insulin-resistant adults before and after pioglitazone treatment. Pioglitazone was linked to fewer adipose macrophages and mast cells, more capillaries, higher elastin content, and better insulin sensitivity. Because the treatment group was small and the analysis was based on secondary tissue studies, the findings are promising but not definitive.

Study Design

Interventions

Pioglitazone

Study Type

Non-randomized CT

Outcomes

Insulin sensitivityAdipose tissue macrophage countAdipose tissue mast cell countCapillary densityAdipose tissue elastin content

Duration and Size

medium–term_3–12_mo

Small size (≤100)

Study Population

Age Range

Middle Aged (40-64)

Sex

MaleFemale

Geography

North America

Other Criteria

with Prediabeteswith Insulin Resistancewith Obesity

Comparison with other Studies

Journal Reference

Spencer M, Yang L, Adu A, et al. Pioglitazone Treatment Reduces Adipose Tissue Inflammation through Reduction of Mast Cell and Macrophage Number and by Improving Vascularity. PLoS One. 2014;9(7):e102190. doi:10.1371/journal.pone.0102190

This research summary and analysis were generated using AI-powered tools to assist in data synthesis and interpretation. While we strive for accuracy and completeness, we encourage readers to verify critical information and consult additional sources as needed. The insights presented reflect an AI-assisted perspective and should not be considered a substitute for expert opinion or independent research.

Stay informed. Stay ahead.

Subscribe now for the latest breakthroughs, expert insights, and cutting-edge updates in diabetes care—delivered straight to your inbox.